0001628280-20-010229.txt : 20200706
0001628280-20-010229.hdr.sgml : 20200706
20200706201238
ACCESSION NUMBER: 0001628280-20-010229
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200702
FILED AS OF DATE: 20200706
DATE AS OF CHANGE: 20200706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Talasaz AmirAli
CENTRAL INDEX KEY: 0001753159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38683
FILM NUMBER: 201014939
MAIL ADDRESS:
STREET 1: 18 ISABELLA AVENUE
CITY: ATHERTON
STATE: CA
ZIP: 94027
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Guardant Health, Inc.
CENTRAL INDEX KEY: 0001576280
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 454139254
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 PENOBSCOT DR.
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 855-698-8887
MAIL ADDRESS:
STREET 1: 505 PENOBSCOT DR.
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
wf-form4_159408074472014.xml
FORM 4
X0306
4
2020-07-02
0
0001576280
Guardant Health, Inc.
GH
0001753159
Talasaz AmirAli
505 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
1
1
0
0
Chairman, President and COO
COMMON STOCK
2020-07-02
4
M
0
54892
4.18
A
2744424
D
COMMON STOCK
2020-07-02
4
S
0
9533
83.4829
D
2734891
D
COMMON STOCK
2020-07-02
4
S
0
44299
83.9309
D
2690592
D
COMMON STOCK
2020-07-02
4
S
0
1060
84.8078
D
2689532
D
COMMON STOCK
2020-07-06
4
M
0
20108
4.18
A
2709640
D
COMMON STOCK
2020-07-06
4
S
0
15000
83.9924
D
2694640
D
COMMON STOCK
2020-07-06
4
S
0
5108
84.40
D
2689532
D
COMMON STOCK
737800
I
Shares held by Talasaz Investments, L.P.
STOCK OPTION (RIGHT TO BUY)
4.18
2020-07-02
4
M
0
54892
0
D
2022-07-13
COMMON STOCK
54892.0
710613
D
STOCK OPTION (RIGHT TO BUY)
4.18
2020-07-06
4
M
0
20108
0
D
2022-07-13
COMMON STOCK
20108.0
690505
D
These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $82.68 to $83.675, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.68 to $84.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.715 to $84.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.40 to $84.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017.
/s/ John Saia, as Attorney-in-Fact for AmirAli Talasaz
2020-07-06